Effectiveness and safety of benralizumab for severe asthma in clinical practice (J-BEST): a prospective study

BACKGROUND: Benralizumab is a humanized, fucosylated, monoclonal antibody that targets the interleukin 5 (IL-5) α receptor. Several phase III trials have shown that benralizumab can significantly reduce the incidence of acute exacerbations and improve lung function in patients with severe asthma. Ho...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ann Transl Med
Egile Nagusiak: Izumo, Takehiro, Tone, Mari, Kuse, Naoyuki, Awano, Nobuyasu, Tanaka, Atsuko, Jo, Tatsunori, Yoshimura, Hanako, Minami, Jonsu, Takada, Kohei, Inomata, Minoru
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AME Publishing Company 2020
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7210162/
https://ncbi.nlm.nih.gov/pubmed/32395482
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2020.04.01
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak